Item 7.01 Regulation FD Disclosure.
During a presentation at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, Avantor, Inc. (the “Company”) provided an update regarding expectations for third quarter results and revised its previously announced expectations for recent acquisitions.
As previously communicated, in the third quarter the Company continues to expect modest acceleration in core organic net sales growth of 50 to 75 basis points as compared to core organic net sales growth of 6.4% in the second quarter of 2022. This translates to 3% to 4% organic net sales growth, an acceleration from 2.3% organic growth in the second quarter. Based on the impact of COVID headwinds, inorganic contributions from recent acquisitions and foreign exchange, the Company expects total reported net sales in the third quarter of approximately $1,840 to $1,850 million.
These third quarter estimates include updated expectations for recent acquisitions of $400 million of total net sales contribution, from $450 million previously communicated. This update reflects the ongoing impacts of foreign exchange, COVID headwinds, supply chain constraints and softening demand in industrial applications in Europe.
The Company also reiterated that it continues to perform well across end markets and geographies, delivering approximately 7% core organic net sales growth, greater than 140 basis points of Adjusted EBITDA margin expansion, and 13% growth in adjusted net income in the first half of 2022, all of which are at the high end or above the Company’s long-term target ranges.
A replay of the presentation is available at https://ir.avantorsciences.com/investors/news-and-events/events/default.aspx.
Forward-Looking and Cautionary Statements
This Form 8-K contains forward-looking statements. All statements other than statements of historical fact included in this Form 8-K are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “likely,” “outlook,” “plan,” “potential,” “project,” “projection,” “seek,” “can,” “could,” “may,” “should,” “would,” “will,” the negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in “Risk Factors” in our most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of September 12, 2022. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.